Some tips to help get started:
There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
397 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial targets patients aged 18-75 with locally advanced or metastatic NSCLC featuring uncommon EGFR mutations, excluding those previously treated with EGFR-TKIs, and tests Sutetinib maleate, an irreversible EGFR tyrosine kinase inhibitor, for its efficacy and safety.
ClinicalTrials.gov ID: NCT06010329
HealthScout AI summary: This trial evaluates the efficacy and safety of fianlimab, an anti-LAG-3 antibody, combined with cemiplimab, an anti-PD-1 antibody, compared to cemiplimab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1 ≥50% who have not received prior systemic treatment.
ClinicalTrials.gov ID: NCT05785767
HealthScout AI summary: This trial is evaluating the efficacy and safety of Sutetinib Maleate Capsule, an investigational irreversible EGFR tyrosine kinase inhibitor, in adult patients with locally advanced or metastatic NSCLC harboring non-resistant uncommon EGFR mutations (L861Q, G719X, and/or S768I), who have had no more than one prior line of chemotherapy.
ClinicalTrials.gov ID: NCT05168566
HealthScout AI summary: This trial targets adult patients with metastatic squamous non-small cell lung cancer and evaluates the efficacy of pembrolizumab combined with carboplatin and paclitaxel/nab-paclitaxel followed by pembrolizumab with or without the antibody-drug conjugate sacituzumab tirumotecan, which targets TROP2, in improving overall survival.
ClinicalTrials.gov ID: NCT06422143
HealthScout AI summary: This trial targets patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer who have progressed after osimertinib treatment, evaluating the efficacy of Dato-DXd, an antibody-drug conjugate targeting TROP2, with or without osimertinib, against standard platinum-based doublet chemotherapy.
ClinicalTrials.gov ID: NCT06417814
HealthScout AI summary: This trial examines EIK1001, a toll-like receptor 7/8 dual agonist, combined with pembrolizumab and chemotherapy, in adults with stage 4 non-small cell lung cancer who haven't received prior systemic treatment and lack actionable tumor mutations.
ClinicalTrials.gov ID: NCT06246110
HealthScout AI summary: This trial involves adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after anti-PD-1/PD-L1 therapy and platinum-based chemotherapy, comparing the investigational anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) with docetaxel to evaluate their impact on overall survival.
ClinicalTrials.gov ID: NCT05671510
HealthScout AI summary: The trial is evaluating the efficacy of rilvegostomig, a bispecific antibody targeting PD-1 and TIGIT, versus pembrolizumab, combined with platinum-based chemotherapy as a first-line treatment for patients with stage IV metastatic squamous non-small cell lung cancer expressing PD-L1 ≥ 1%, excluding those with actionable driver oncogenes.
ClinicalTrials.gov ID: NCT06692738
HealthScout AI summary: The trial targets untreated patients with KRAS G12C-mutant, locally advanced or metastatic NSCLC, comparing the efficacy and safety of LY3537982, a KRAS G12C inhibitor, with pembrolizumab, with or without pemetrexed and platinum, against placebo and pembrolizumab regimens. Eligibility varies by PD-L1 expression level: ≥50% for Part A or any level for Part B.
ClinicalTrials.gov ID: NCT06119581
HealthScout AI summary: This trial investigates the efficacy of savolitinib, a MET inhibitor, in combination with osimertinib compared to platinum-based chemotherapy in adult patients with EGFR-mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed following osimertinib therapy.
ClinicalTrials.gov ID: NCT05261399